Search clinical trials for: Temozolomide and O6-Benzylguanine

Total 954 results

Duke University
National Institutes of Health (NIH); Keryx / AOI Pharmaceuticals, Inc.

Completed

Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma

Glioblastoma Multiforme | Anaplastic Glioma

United States
Duke University
Schering-Plough; Keryx / AOI Pharmaceuticals, Inc.

Completed

Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM

Glioblastoma | Gliosarcoma

United States
National Cancer Institute (NCI)

Completed

O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors

Brain and Central Nervous System Tumors

United States
National Cancer Institute (NCI)

Completed

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Sarcoma | Kidney Cancer | Unspecified Childhood Solid Tumor, Protocol Specific | Ovarian Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Liver Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

United States
Duke University
National Cancer Institute (NCI)

Completed

Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma

Brain and Central Nervous System Tumors

United States
Keryx / AOI Pharmaceuticals, Inc.

Terminated

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Glioma | Astrocytoma | Oligoastrocytoma | Oligodendroglioma

United States
National Cancer Institute (NCI)

Terminated

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Brain and Central Nervous System Tumors

United States
Duke University
Pharmacia; Keryx / AOI Pharmaceuticals, Inc.

Completed

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

Glioblastoma | Gliosarcoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

O(6)-Benzylguanine in Treating Patients With Malignant Glioma

Brain and Central Nervous System Tumors

United States
University of Chicago
National Cancer Institute (NCI)

Completed

O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Choroid Plexus Tumor | Childhood Craniopharyngioma | Childhood Ependymoblastoma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma and other conditions

United States
Stanton Gerson MD
National Cancer Institute (NCI)

Completed

BG & TMZ Therapy of Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma

Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System

United States
National Cancer Institute (NCI)

Completed

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Melanoma (Skin)

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Lymphoma | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

Brain and Central Nervous System Tumors

United States, Canada, Australia
Children's Hospital Medical Center, Cincinnati
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas

Brain and Central Nervous System Tumors
Duke University
National Cancer Institute (NCI)

Withdrawn

Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Brain and Central Nervous System Tumors
Duke University
National Cancer Institute (NCI)

Completed

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

Brain and Central Nervous System Tumors

United States
Duke University
National Cancer Institute (NCI)

Completed

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

Brain and Central Nervous System Tumors

United States
University of Chicago
National Cancer Institute (NCI)

Completed

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

Sarcoma

United States
Duke University
National Cancer Institute (NCI)

Completed

Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme

Recurrent Adult Brain Tumor

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Leland Metheny
National Cancer Institute (NCI)

Recruiting

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM)

Glioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial Glioblastoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States
National Cancer Institute (NCI)

Terminated

Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United States
National Cancer Institute (NCI)

Terminated

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United States
Children's Hospital Medical Center, Cincinnati

Terminated

Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy

Glioblastoma Multiforme (WHO Grade IV) | Anaplastic Astrocytoma (WHO Grade III)

United States
National Cancer Institute (NCI)

Completed

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7

United States
Massachusetts General Hospital
Novartis

Active, not recruiting

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Lung Cancer

United States
Medical University of Gdansk

Terminated

Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery

Acute Renal Failure

Poland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Withdrawn

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Human Immunodeficiency Virus 1 Positive | Stage I Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Stage I Adult Non-Hodgkin Lymphoma | Stage II Adult Non-Hodgkin Lymphoma | Stage III Adult Non-Hodgkin Lymphoma | Stage IV...

United States
Guangzhou Medical University

Unknown

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

Small Cell Lung Cancer | Metastatic Carcinoma

China
Bradmer Pharmaceuticals Inc.

Terminated

Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy (Glass-Art)

Glioblastoma Multiforme
Peking Union Medical College Hospital
Beijing Tiantan Hospital; Tianjin Medical University General Hospital

Unknown

Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas

Malignant Gliomas

China
Novartis Pharmaceuticals

Completed

A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Glioblastoma

Australia, Spain, Canada, United States
Activartis Biotech

Completed

Dendritic Cell Cancer Vaccine for High-grade Glioma (GBM-Vax)

Glioblastoma Multiforme

Austria
University of Southampton
Bristol-Myers Squibb

Recruiting

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE)

Cancer of Esophagus | Adenocarcinoma - GEJ

United Kingdom
Haukeland University Hospital
University of Oslo; Oslo University Hospital; University Hospital of North Norway and other collaborators

Recruiting

Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) (BORTEM-17)

Glioblastoma

Norway
Yunpeng Liu

Unknown

Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic

Extensive Stage Small Cell Lung Cancer

China
Duke University
National Cancer Institute (NCI)

Completed

Temozolomide in Treating Patients With Progressive Low-Grade Glioma

Brain and Central Nervous System Tumors

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Lung Cancer

United States
European Organisation for Research and Treatment...

Completed

Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

Brain and Central Nervous System Tumors

France, Denmark, Netherlands, Belgium, Germany, Sweden, United Kingdom, Finland, Portugal, Austria, Hungary, Italy
Fred Hutchinson Cancer Center

Terminated

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Glioblastoma | Gliosarcoma

United States
Yong-Kil Hong
National Cancer Center, Korea; Samsung Medical Center; Seoul St. Mary's Hospital and other collaborators

Completed

Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma (METT)

Glioblastoma

Korea, Republic of
Medical University of South Carolina

Terminated

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma

Glioma | Astrocytoma | Brain Tumor | Glioblastoma Multiforme

United States
Clinica Universidad de Navarra, Universidad de...
DNAtrix, Inc.

Completed

Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (D24GBM)

Glioblastoma Multiforme | Recurrent Tumor

Spain

Search clinical trials for: Temozolomide and O6-Benzylguanine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations